Sign up USA
Proactive Investors - Run By Investors For Investors

Loxo Oncology shares soar on rosy data from Phase 1 cancer drug trial

Loxo 292 is meant for cancer patients with faulty RET genes where two genes have become fused together
Cancer headline in a newspaper
Loxo Oncology's shares are trading sharply higher in morning trade

Shares of Loxo Oncology Inc. (NASDAQ: LOXO), a biopharmaceutical company, soared Thursday after the cancer specialist revealed that its drug LOXO-292 shrunk tumors in as many as 70% of cancer patients who took part in an ongoing Phase 1 clinical trial.

In response to the news, investors sent up Loxo Oncology shares by 21% to US$168.70.

Stephen Willey, an analyst with Stifel, also raised his price target on the company's stock to US$190, arguing that the potency of LOXO-292 sets Loxo Oncology apart from its competitors who produce less-effective RET inhibitors.

LOXO-292, which addresses RET gene mutated cancers, was handled well by patients with late-stage cancers who had exhausted other available treatments.

The medicine is meant for cancer patients with faulty RET genes where two genes have become fused together, which fuels cancer growth.

In cancer patients with fused RET genes, roughly 69% of those who were assessed in Loxo's study saw tumors shrink, regardless of the type of cancer, and the tumors were reduced by as much as 67% in size.

A short analysis of preliminary data from its ongoing Phase 1 clinical trial for LOXO-292 was unveiled ahead of a presentation next month at the American Society of Clinical Oncology’s Annual meeting to be held from June 1-5 in Chicago.

 

View full LOXO profile View Profile

Related Articles

picture of platinum
July 10 2017
The miner has notched up another quarter of record production at its Tharisa mine in South Africa
Picture of Malaysian city
May 09 2018
The group’s ability to provide benefits to the retail sector was demonstrated in 2017.
picture of oilfield
March 14 2018
Svetlana Mendesh, Chief Financial Officer, said 2016 results were in line with its projections and local market trends.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use